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Background:  Excess  mortality  due  to seasonal  inﬂuenza  is  substantial,  yet  quantitative  estimates  of the
beneﬁt  of  annual  vaccination  programs  on  inﬂuenza-associated  mortality  are  lacking.
Methods:  We  estimated  the  numbers  of  deaths  averted  by  vaccination  in four  age  groups  (0.5  to  4,  5 to 19,
20 to 64 and  ≥65  yrs.)  for  the nine  inﬂuenza  seasons  from  2005/6  through  2013/14.  These  estimates  were
obtained  using  a Monte  Carlo  approach  applied  to  weekly  U.S.  age  group-speciﬁc  estimates  of  inﬂuenza-
associated  excess  mortality,  monthly  vaccination  coverage  estimates  and  summary  seasonal  inﬂuenza
vaccine effectiveness  estimates  to obtain  estimates  of  the  number  of  deaths  averted  by  vaccination.  The
estimates  are  conservative  as  they  do  not  include  indirect  vaccination  effects.
Results:  From  August,  2005  through  June,  2014,  we estimated  that  40,127  (95%  conﬁdence  interval  [CI]
25,694  to 59,210)  deaths  were  averted  by  inﬂuenza  vaccination.  We  found  that  of all  studied  seasons  the
most  deaths  were  averted  by  inﬂuenza  vaccination  during  the  2012/13  season  (9398; 95% CI  2,386  to
19,897)  and  the  fewest  during  the  2009/10  pandemic  (222;  95%  CI 79  to 347).  Of  all  inﬂuenza-associated
deaths averted,  88.9%  (95%  CI 83 to 92.5%)  were  in  people  ≥65  yrs.  old.
Conclusions: The  estimated  number  of  deaths  averted  by  the  US annual  inﬂuenza  vaccination  program
is  considerable,  especially  among  elderly  adults  and  even  when  vaccine  effectiveness  is modest,  such  as
in  the  2012/13  season.  As indirect  effects  (“herd  immunity”)  of vaccination  are  ignored,  these  estimates
represent  lower  bound  estimates  and  are  thus  conservative  given  valid  excess  mortality  estimates
ublis© 2015  The  Authors.  P
. Introduction
In the U.S., seasonal inﬂuenza has been estimated to be associ-
ted with an average of ∼25,000 [1,2] to 35,000 [3] annual deaths.
n 1960, annual inﬂuenza vaccination was recommended in the
.S. for persons aged ≥65 yrs., for those with chronic debilitating
isease as well as for pregnant women [4]. Inﬂuenza vaccination
ecommendations were broadened over time until 2010, when
nnual inﬂuenza vaccination was recommended for all people ≥6
onths of age [5]. Recently, Kostova et al. [6] found a substantial
eneﬁt of the current inﬂuenza vaccination program in the United
 The ﬁndings and conclusions in this report are those of the authors and do not
ecessarily represent the views of the Centers for Disease Control and Prevention.
∗ Corresponding author at: Centers for Disease Control and Prevention, 1600
lifton Road NE, MS  A-20, Atlanta, Georgia 30333. Tel.: +1 404 639 7254.
E-mail addresses: vor1@cdc.gov, ivo.foppa@gmail.com (I.M. Foppa).
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.042
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
States on the total number of inﬂuenza cases and hospitalizations,
based on data on laboratory-conﬁrmed inﬂuenza-associated hos-
pitalizations. Similar estimates of mortality averted by vaccination
would further help prioritize public health interventions and facil-
itate communications regarding the need and value of inﬂuenza
prevention. We sought to estimate the number of deaths averted by
annual inﬂuenza vaccination in the United States from the inﬂuenza
seasons 2005/06 through 2013/14. Our aim is to provide conserva-
tive seasonal and age group-speciﬁc estimates for the number of
deaths averted by the US inﬂuenza vaccination program.
2. Methods2.1. Averted deaths formula
The number of deaths averted by inﬂuenza vaccination dA was
estimated by multiplying the number of deaths expected in the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Vaccine effectiveness estimates by study type, season and age range with their
respective literature references.
Season Age range (yrs.) Study type VE (95% CI) Reference
2005/06 ≥0.5 TNDa 21 (−52, 59)b [10]
2005/06 18–48 RCTc 16 (−171, 70) [11]
2005/06 ≥5 TND 61 (26, 79) [12]
2006/07 ≥0.5 TND 52 (22, 70) [10]
2006/07 ≥9 TND 46 (17, 65) [13]
2007/08 18–49 RCT 68 (46, 81) [14]
2007/08 0.5–4 TND 39 (2, 62) [15]
2007/08 ≥0.5 TND 37 (22, 49) [15]
2007/08 ≥0.5 TND 60 (45, 71) [16]
2008/09 ≥0.5 TND 56 (41, 67) [17]
2009/10 ≥0.5 TND 56 (23, 75)d [18]
2010/11 0.5–4 TND 67 (53, 77) [19]
2010/11 5–19 TND 59 (45, 70) [19]
2010/11 20–64 TND 50 (36, 62) [19]
2010/11 ≥65 TND 36 (−22, 66) [19]
2011/12 0.5–4 TND 49 (12, 70) [20]
2011/12 5–19 TND 50 (29, 65) [20]
2011/12 20–64 TND 46 (28, 59) [20]
2011/12 ≥65 TND 43 (−18, 72) [20]
2012/13 0.5–4 TND 58 (40, 71) [21]
2012/13 5–19 TND 46 (32, 57) [21]
2012/13 20–64 TND 52 (43, 60) [21]
2012/13 ≥65 TND 32 (0, 56) [21]
2013/14 0.5–4 TND 47 (14, 67) [22]
2013/14 5–19 TND 56 (37, 69) [22]
2013/14 20–64 TND 52 (42, 61) [22]
2013/14 ≥65 TND 39 (0, 65) [22]
a Case test-negative design (see, e.g.[7]).
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Table 2
Empirical distributions of vaccine effectiveness by season and age group as they
were used for the calculation of averted deaths.
Season 0.5–4 yrs 5–19 yrs 20–64 yrs ≥65 yrs
2005/06 44 (3,77)a 44 (3,77) 44 (3,77) 29 (2,65)
2006/07 49 (19,68) 49 (19,68) 49 (19,68) 32 (12,58)
2007/08 39 (8,62)b 42 (24,74) 42 (24,74) 29 (13,61)
2008/09 56 (42,67) 56 (42,67) 56 (42,67) 39 (22,59)
2009/10 56 (21,74) 56 (21,74) 56 (21,74) 36 (13,65)
2010/11 67 (52,77)b 59 (46,70)b 50 (35,61)b 37 (5,67)b
2011/12 49 (15,71)b 50 (30,65)b 45 (30,58)b 45 (7,74)b
2012/13 58 (40,70)b 46 (33,58)b 52 (43,60)b 31 (5,56)b
2013/14 47 (17,67)b 56 (37,69)b 52 (41,60)b 40 (7,64)bb Point estimate (95% conﬁdence interval).
c Randomized controlled trial.
d Effectiveness of monovalent pandemic vaccine.
bsence of vaccination (D) by the proportion effectively vaccinated,
.e.:
A = D × v (1)
here, v denotes vaccination coverage (seasonal inﬂuenza vaccine)
nd  denotes vaccine effectiveness (VE) of the seasonal inﬂuenza
accine. The number of excess deaths in the absence of vaccina-
ion is calculated by dividing the number of excess deaths due to
nﬂuenza under the current vaccination program (ε) by the propor-
ion not protected by vaccination (1 − v), i.e.:
 = ε
1 − v . (2)
Note that all quantities are indexed by time. For instance, dA may
efer to the deaths averted in a given month.
.2. Data
.2.1. Vaccine effectiveness (VE)
We used published estimates of VE against acute respiratory
llness (ARI) due to any laboratory-conﬁrmed inﬂuenza virus infec-
ion for the inﬂuenza seasons (Northern Hemisphere) 2005/6,
hrough 2013/14 which were derived from either case test-
egative control studies [7–9] or from randomized controlled trials,
onducted in outpatient settings in North American populations.
e used estimates that were from subjects of a broad age range
e.g. 6 months or older or 18–48 yrs.) or were restricted to one
f our age groups (e.g. ≥65 yrs.) [10–22] (Table 1). Up to 2010/11
e mostly used the same estimates Kostova et al. [6] used for their
nalysis of cases and hospitalizations averted by inﬂuenza vaccina-
ion; however, we excluded one unpublished study (see reference
1 in [6]) and one study that included non-North American popu-
ations [23], added one study that had been published since [16] as
ell as three studies estimating VE for the three recent inﬂuenza
easons (2011/12, 2012/13 and 2013/14, respectively) [20,24,25].a Point estimate in percentage (95% conﬁdence interval).
b Based on age group-speciﬁc estimate.
VE is believed to decline with increasing age above ∼65 yrs. [26],
but there are few published estimates of VE among those 65 yrs.
old, particularly for speciﬁc seasons. If, for a particular season, no
age group–speciﬁc estimates were available for persons aged ≥65
yrs. (e.g. prior to 2008/9), we assumed, in concordance with [6], the
VE of that age group to be 0.7 of the VE reported for the younger age
group on average (uniform distribution in the range 40%–100% to
reﬂect uncertainty). The assumption of an average attenuation of
30% is also compatible with observations for the seasons when VE
estimates for persons <65 yrs. old and ≥65 yrs. old were available
(2010/11, 2011/12 and 2012/13). In those years, the average rela-
tive VE for those ≥65 yrs. old (VE≥65/VE<65; iteratively calculated
from draws from sampling distributions) was  73% (95% CI 10% to
176%). Table 2 displays the empirical distributions of annual age
group-speciﬁc VEs.
2.2.2. Vaccination coverage (VC)
Monthly VC estimates by age group were obtained from the
National Health Immunization Survey (NHIS) (Dr. P Lu, CDC, per-
sonal communication). Coverage was  assumed constant over a
month. For the months of June and July for which no coverage
estimates are available, zero coverage was assumed. To account
for a two-week delay in the development of effective immunity
after vaccination, we  assumed that the effective coverage in a given
month was the average between last month’s and current month’s
coverage. For the season 2013/14, for which no data were avail-
able at the time of this analysis, the same monthly coverage was
assumed as in 2012/13 season. Vaccination coverage increased over
the study period, especially in subjects under 65 yrs. of age, but
there was  little change between 2011/12 and 2012/13. For example,
estimated coverage, in the age group 6 months to 4 yrs., was 42.7%
(95% CI 39.8%, 45.8%) and 42.6% (39.8%, 45.6%) in November, respec-
tively, and 62.4% (58.9%, 65.9%) and 63.5% (60.0%, 67.1%), in May
of the following year, respectively. The assumption of unchanged
coverage thus tends to understate the number of deaths averted.
2.2.3. Mortality data
To estimate the weekly number of deaths attributable to
inﬂuenza by age group we used weekly age group-speciﬁc (0.5
to 4 yrs., 5 to 19 yrs., 20 to 64 yrs., 65+ yrs.) mortality data from
the National Center for Health Statistics (NCHS) for 2005 through
2012. Deaths were categorized using the International Classiﬁca-
tion of Diseases, 10th Revision (ICD-10) codes. For the purposes of
estimating deaths potentially averted by the inﬂuenza vaccination
program, we  focused on underlying causes of death categorized
as respiratory and circulatory (R&C) in nature, corresponding to
ICD-10 codes I00-I99 and J00-J99. For each mortality record, a
single underlying cause is listed, deﬁned as “the disease or injury
which initiated the train of morbid events leading directly to death,
or the circumstances of the accident or violence which produced
the fatal injury”, in accordance with the rules of the International
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Table  3
Estimated numbers of excess deaths due to inﬂuenza (all ages) for the seasons 2005/6 through 2012/13 (August through July of the following year).
Season 6 months–4 yrs 5–19 yrs 20–64 yrs ≥65 yrs All
2005/6 21 (12,34)a 26 (16,40) 1483 (1122,1848) 9185 (7545,10774) 10714 (9015,12363)
2006/7 65 (41,92) 82 (56,110) 1442 (1019,1925) 9002 (6671,11367) 10612 (8226,13003)
2007/8  76 (51,104) 93 (66,122) 3297 (2672,3934) 18916 (15932,22043) 22385 (19246,25567)
2008/9 92 (58,131) 114 (78,151) 1844 (1250,2523) 10209 (7056,13288) 12275 (9041,15445)
2009/10 110 (63,165) 276 (217,339) 5293 (4279,6356) 3939 (2694,6107) 9656 (7967,12047)
2010/11 60 (36,89) 89 (63,119) 4049 (3341,4757) 17492 (14682,20363) 21680 (18693,24711)
2011/12 28 (16,43) 40 (27,56) 2048 (1692,2421) 10019 (8402,11717) 12151 (10467,13880)
2012/13 84 (43,133) 99 (55,152) 6084 (4920,7384) 30822 (25891,35924) 37102 (31868,42422)
2013/14 51 (32,80) 105 (80,156) 2594 (2063,3375) 4718 (3668,6176) 7505 (6260,9140)
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a Median of posterior distribution (95% credible interval).
lassiﬁcation of Diseases [27]. For the time period for which the
CHS data was not yet available (January, 2013 through July, 2014)
e assumed the same relationship between inﬂuenza incidence
nd mortality as for the preceding time period.
.2.4. Inﬂuenza indicator
To construct an indicator of inﬂuenza-associated mortality, we
sed weekly proportion of respiratory samples testing positive
or speciﬁc types (A,B) and subtypes (A(H1N1), A(2009 H1N1),
(H3N2)) of inﬂuenza from the U.S. World Health Organization
WHO) Collaborating Laboratories and the National Respiratory and
nteric Virus Surveillance System (NREVSS) [28] from the eight sea-
ons, 2005/6 through 2013/14. The number of speciﬁc inﬂuenza A
ubtypes was augmented by adding the product of the weekly pro-
ortion of a speciﬁc subtype in the subtyped inﬂuenza A specimens
nd the number of unsubtyped or unsubtypable inﬂuenza A viruses.
hese proportions were multiplied by the number of inﬂuenza-
ike illness (ILI) visits per reporting provider in the U.S. Outpatient
LI Surveillance Network (ILINet) [28]. This inﬂuenza indicator is
erived in Supplement S2.
.3. Excess mortality estimation
We  estimated U.S. excess mortality due to inﬂuenza using a sta-
istical approach structurally similar to one previously described
2], for the period of the ﬁrst epidemiological week of October of
005 through the last week of July, 2014. Brieﬂy, we modeled the
eekly age group-speciﬁc R&C mortality (ICD-10 codes I00-I99,
00-J99) as a gamma-Poisson mixture [30] (negative Binomial) dis-
ribution with the Poisson parameter being a function of seasonally
eriodic variations, inﬂuenza incidence indicators (Supplement S2)
nd temporal trends to accommodate both demographic changes,
s well as changes in the surveillance process and/or the virulence
f the circulating inﬂuenza types/subtypes. The model is described
n detail in Supplement S1. The model was ﬁt using Markov chain
onte Carlo (MCMC) algorithms as implemented in JAGS [31] and
nterfaced with R [29] by the R-package rjags [32]. For most model
arameters we assumed ﬂat Normal priors centered at 0, with vari-
nce 1.0E6, but truncated at zero, except for the parameters driving
he sinusoidal baseline mortality (see Supplement S1). For the size
arameters of the negative Binomial distributions, uniform priors
ere assumed (range 0 to 1.0E6). Three thousand samples were
btained by selecting each ﬁfth sample of 5000 iterations in three
hains, resulting in 3000 samples for each parameter, after a burn-
n period of 20,000 iterations.
The weekly excess mortality for each age group was directly
btained from the model coefﬁcients (see Supplement S1) and was
ummed over seasons. Following Kostova et al. [6] we only consid-
red the weeks from October through April for most seasons except
or the 2009/10 pandemic, when we used the months from May
2008) through April (2010), as well as for the seasons 2011/2012,32437) 114346 (97171,132006) 144109 (125586,161988)
(October, 2011 through September, 2012) and 2013/14 (October,
2013 through July, 2014). The construction of Monte Carlo conﬁ-
dence intervals is described in Supplement S5.
3. Results
During the study period, the highest numbers of deaths associ-
ated with inﬂuenza occurred during the season 2012/13, followed
by 2007/8 and 2010/11 (Table 3). Each of these three seasons
were dominated by circulation of inﬂuenza A(H3N2) and inﬂuenza
B viruses (Fig. 1). There were relatively few inﬂuenza-associated
excess deaths in the 2006/7, 2008/9, 2009/10 and 2013/14 seasons,
when inﬂuenza A(H1N1) and inﬂuenza B viruses predominated
(Figs. 1 and 2, Table 3).
The number of deaths averted each season by vaccination
depended linearly on the number of excess deaths as well as on
the odds of being effectively vaccinated, v1−v (see Eq. (1) and (2).
To the extent that VE as well as vaccination coverage vary by sea-
son, numbers of deaths potentially averted by vaccination would
be therefore expected to be more variable than the number of esti-
mated excess deaths attributed to inﬂuenza (Table 4). This becomes
particularly evident when comparing the 2009/10 A(H1N1)pdm09
pandemic, when an estimated 9656 (95% CI 7967 to 12,047) deaths
were estimated to be associated with inﬂuenza, with the 2012/13
season when close to 40,000 deaths, nearly four times as many,
were attributed to inﬂuenza (Table 3). However, more than forty
times more deaths were estimated to be averted during the 2012/13
compared to the 2009/10 season (Table 4). This apparent discrep-
ancy was  largely due to the timing of vaccination: the monovalent
vaccine against pandemic inﬂuenza A(H1N1)pdm09 became avail-
able in the United States on a broad basis only at the tail end of
the 2009/10 pandemic while in 2012/13, like in most seasons, vac-
cination uptake is concentrated before the bulk of the seasonal
epidemic. Over the nine seasons included in this study, we esti-
mated that over forty thousand deaths were averted by the US
inﬂuenza vaccination program (Table 4). Almost ninety percent of
the deaths averted (88.9%; 95% CI 83 to 92.5%, not shown) would
have occurred, in the absence of vaccination, in those ≥65 yrs. old.
Over the whole study period, we  estimated that the inﬂuenza
mortality prevented by the vaccination program (i.e., the averted
fraction) was a little less than a fourth (Table 5). The overall averted
fraction was  highest in the oldest age group, driven by high vacci-
nation coverage, followed by the youngest age group. The fraction
averted in the intermediate age categories was  substantially lower
(Table 5). In all age groups the averted fraction was substantially
higher at the end than the beginning of the study period (Table 5).
During the 2013/14 season in persons aged ≥65 yrs., over a fourth
of the inﬂuenza deaths expected in the absence of vaccination were
averted by vaccination. By contrast, during the 2009/10 pandemic,
when mortality rates were reduced in that age group, only about
one percent of the deaths were averted by vaccination, but the
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(H1N1) pdm09 and B viruses, October, 2005 through July, 2014.
roportion averted was almost seven percent in the youngest age
roup.
. DiscussionWe  estimated that annual inﬂuenza vaccination averted almost
 fourth of predicted inﬂuenza-associated deaths during the nine
easons 2005/6 through 2013/14. Almost 90% of the averted deaths
ig. 2. The median number of deaths associated with inﬂuenza (excess mortality = EM) a
ctober, 2005 through July, 2014.) and the number of specimens testing positive for inﬂuenza A(H1N1), A(H3N2),
would have occurred among persons aged ≥65 yrs. Mortality
due to seasonal inﬂuenza is substantial, especially among elderly
adults [2,3,33–46]. Kostova et al. [6] also found the predominance
of averted hospitalizations from inﬂuenza vaccination in those ≥65
yrs. old. The estimated numbers of deaths averted by vaccination
varied by season with most deaths estimated to be averted during
2012/13 and the fewest deaths averted during 2009/10. Using
very different methods and data, Borse et al. [47] also found that
nd the indicators for inﬂuenza A(H1N1), A(H3N2), A(H1N1) pdm09 and B viruses,
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Table  4
The estimated number of deaths averted by inﬂuenza vaccination from August, 2005 through July, 2013, by inﬂuenza season and age group.
Season 6 months–4 yrs 5–19 yrs 20–64 yrs ≥65 yrs All
2005/6 4 (0,9)a 2 (0,4) 143 (11,292) 2094 (141,6872) 2250 (151,7138)
2006/7 16 (5,30) 8 (3,14) 174 (63,293) 2406 (712,5782) 2606 (806,6085)
2007/8 16 (2,32) 10 (4,20) 409 (194,799) 4647 (1715,13689) 5112 (1965,14393)
2008/9 34 (19,55) 20 (13,29) 339 (209,509) 3575 (1574,7338) 3983 (1920,7787)
2009/10 8 (2,15) 14 (5,21) 153 (56,229) 43 (9,124) 222 (79,347)
2010/11 34 (18,55) 24 (15,35) 709 (456,971) 5915 (598,14091) 6692 (1406,15019)
2011/12 12 (2,25) 10 (5,15) 351 (210,511) 4456 (364,10865) 4821 (811,11250)
2012/13 37 (17,69) 21 (10,36) 1253 (909,1663) 8088 (989,18528) 9398 (2386,19897)
2013/14 18 (5,37) 29 (17,47) 559 (386,778) 1799 (210,4054) 2412 (847,4662)
All  seasons 182 (122,258) 139 (103,183) 4144 (3298,5141) 35563 (21337,54505) 40127 (25694,59210)
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umbers of deaths averted by vaccination during the 2009/10
nﬂuenza A(H1N1) pandemic, when the pandemic vaccine was not
idely available until well after the peak of inﬂuenza infections
ad occurred, were low. Their estimate of 305 deaths averted was
emarkably similar to ours (222).
The differences in the averted death estimates by season were
elated to the inter-seasonal differences in inﬂuenza-associated
xcess mortality and vaccine effectiveness estimates. The sub-
tantial inter-seasonal variability in inﬂuenza-associated excess
ortality has been attributed to differences in the intensity of
easonal inﬂuenza epidemics [48], virulence of seasonally predom-
nant circulating inﬂuenza viruses [44,49] and population-based
evels of immunity [44]. The factors that inﬂuence seasonal differ-
nces in vaccine effectiveness are complex, but are related in part
o antigenic similarities between circulating and vaccine viruses.
Ecological studies, using non-speciﬁc outcomes, have cast doubt
n the effectiveness of inﬂuenza vaccine to avert deaths in adults
65 yrs. of age [39,50]. Clinical trial data for that age group are
carce and suggest an efﬁcacy below 50% [51]. This is also true
or estimates from observational studies for the inﬂuenza seasons
010/11 [19], 2011/12 [20], 2012/13 [21] and 2013/14 [22]. Yet,
ven with our conservative method, we estimated a substantial
umber of deaths averted by vaccination in this age group, even
uring years with lower vaccine effectiveness estimates for elderly
dults compared to younger adults.
Our ﬁndings should be interpreted in light of several limitations.
irst and most importantly, we did not consider the indirect effects
f inﬂuenza vaccination programs [52]. An important consequence
f an indirect effect is the existence of a critical vaccination cov-
rage threshold (i.e. v) above which transmission of the targeted
gent is disrupted [53]. If a population is vaccinated above that
hreshold, then excess mortality due to that agent would tend to
ero and, in that situation, all deaths would have been averted.
owever, Eq. (1) suggests that, when inﬂuenza transmission is
able 5
he estimated proportion (in percent) of deaths averted by inﬂuenza vaccination from Au
Season 6 months–4 yrs 5–19 yrs 2
2005/6 15.2 (0.9,26.6)a 6.5 (0.4,11.3) 
2006/7 20.3 (8.1,28.1) 9.3 (3.8,12.9) 1
2007/8 17.4 (3.6,28.1) 9.3 (5.1,16.4) 1
2008/9 27.5 (20.5,33) 15.3 (11.4,18.2) 1
2009/10 6.9 (2.5,9.8) 4.8 (1.8,6.6) 
2010/11 36.4 (28.1,42.3) 21.8 (16.8,25.9) 1
2011/12 29.6 (8.6,43.3) 19.6 (11.3,25) 1
2012/13 31.3 (21.6,38.3) 17.5 (12.6,22.1) 1
2013/14 26.2 (8.6,37.8) 21.6 (14.4,27) 1
All  seasons 23.5 (19.8,27) 13 (11.2,14.8) 1
a Median (95% empirical conﬁdence interval).effectively disrupted resulting in the absence of excess mortality,
the calculated number of deaths averted would be zero. Such ﬁnd-
ing clearly would be incorrect since, in fact, all deaths would have
been averted. This contradiction arises because Eq. (1) requires a
100% effective coverage (coverage times effectiveness = v) level
to completely eliminate infection-related deaths, whereas elimi-
nation can actually be achieved below 100% effective coverage if
herd immunity is accounted for. Furthermore, if inﬂuenza mortal-
ity in a particular season was low because of vaccination, a low
excess mortality and thus averted deaths estimate would result.
By focusing only on direct effects, our estimates of averted deaths
therefore are conservative (see also Supplement S4). While the
degree of underestimation will need to be quantiﬁed, especially for
a more accurate valuation of inﬂuenza vaccination, our estimates
are substantial enough to support the need for annual inﬂuenza
vaccination campaigns.
Second, our estimates of the number of deaths averted by
vaccination are driven by excess deaths estimates which were
obtained by an “ecological” (as opposed to individual-based) study
design. These kinds of analyses are prone to confounding [54].
Even though we were unable to directly adjust for confounding
we sought to improve the validity of our excess mortality esti-
mates by using a novel inﬂuenza incidence indicator which is
similar to the indicator proposed by Goldstein et al. [55], rather
than using only the proportion of tests “positive” for inﬂuenza.
The resulting excess mortality estimates were, in fact, proportional
to laboratory-conﬁrmed inﬂuenza hospitalizations [6] (data not
shown), suggesting good validity. Still, over-estimation of inﬂuenza
associated excess mortality remains a possibility.
Third, we assumed that the relationship between inﬂuenza
type and subtype-speciﬁc incidence and mortality was similar
for the period from 2005 through 2012, for which we  had com-
plete NCHS mortality data and the period from January 2013
through July 2014, for which we  lacked data. It is possible, although
gust, 2005 through July, 2013, by inﬂuenza season and age group.
0–64 yrs 65+ yrs All
8.8 (0.5,15.3) 18.9 (0.9,42.5) 17.9 (0.8,39.6)
1.1 (4.5,15.2) 21.1 (8.1,37.6) 19.8 (7.8,35)
0.9 (5.9,19.1) 19.6 (8.6,41.5) 18.5 (8.4,38.7)
5.8 (11.8,18.6) 26.3 (14.9,40.2) 24.6 (14.8,37.4)
2.8 (1.1,3.9) 1.1 (0.3,2.4) 2.3 (0.8,3.2)
5 (10.4,18.7) 26.5 (3.4,45.6) 24.6 (6,41.7)
4.7 (9.4,18.8) 32 (5.4,51.4) 29.5 (7.1,47.4)
7.2 (14.2,19.8) 21 (3,37.2) 20.4 (5.8,34.6)
7.9 (14.1,21) 28 (4.8,45.1) 24.5 (10,37.7)
2.8 (11.2,14.4) 24 (16.4,32.1) 22 (15.6,29)
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nlikely, that this relationship change which would have biased our
esults.
Fourth, most vaccine effectiveness estimates were based on
tudies with an outcome of laboratory conﬁrmed inﬂuenza associ-
ted ambulatory care visits for acute respiratory infection. Vaccine
ffectiveness estimates for more severe outcomes, such as hos-
italization, with laboratory-conﬁrmed inﬂuenza are limited and
accine effectiveness estimates for laboratory-conﬁrmed inﬂuenza
ssociated deaths are lacking entirely. However, several published
tudies suggest that the vaccine effectiveness estimates from stud-
es with laboratory conﬁrmed inﬂuenza associated hospitalization
utcomes are similar to or higher [56–58] than the estimates used
n our model. We  did not use these studies because they either were
onducted among non-North American populations [58] or because
f the fact that the case test-negative design has not yet been
alidated for hospitalization outcomes [56,57]. To the extent that
he VE estimates used in our analysis were invalid, the estimated
verted fraction will be biased as was shown for hospitalizations
verted by vaccination [59]. In our own sensitivity analysis for the
ge group ≥65 yrs. we found that, even under most adverse con-
itions (VE = 10%) in a moderately severe seasons such as 2012/13
ubstantial numbers of deaths can be averted by the inﬂuenza vac-
ination program (2,129; 95% CI 1785 to 2481) (see Supplement
6).
Finally, as an infectious phenomenon, inﬂuenza incidence is
patially heterogeneous [60] and vaccination coverage may  vary
ubstantially by region [61]. Our analysis, however, ignored any
patial heterogeneity in inputs and modeled outcomes. Averted
eaths may  thus be underestimated, even in the absence of bias.
or the sake of the argument, assume that in a speciﬁc geographic
egion, vaccination against inﬂuenza is above a critical threshold
evel, such that inﬂuenza transmission is disrupted. Consequently,
he true excess mortality due to inﬂuenza in that geographic region
ould be close to zero, contributing little to overall excess mortality
nd resulting in a “diluted” averted deaths estimate.
. Conclusions
We  estimated that a substantial number and proportion of
nﬂuenza-related deaths were averted by recent U.S. inﬂuenza
accination campaigns, even when indirect beneﬁts of vaccina-
ion were not considered. Our ﬁndings support annual inﬂuenza
accination in the United States and suggest that both increased
accination coverage and increased vaccine effectiveness would
esult in even more deaths averted.
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